Forma Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Forma Therapeutics Inc.
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
AstraZeneca and Moderna also shone as the pharma, biotech and allied industries came together in London on 30 November to celebrate a year of exceptional achievement at the 18th Annual Scrip Awards, hosted by the actor, comedian and presenter Stephen Mangan.
- Drug Discovery Technologies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.